Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeucaWAR:NEU -0.27%97 Buyback Yield % is 0.11 as of Jul. 26, 2026, which is 89% below its 10-year median of 1.00. GuruFocus rates WAR:NEU with a GF Score™ of 97/100 and a GF Value™ of zł896.12 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 39 Medical Distribution companies, Neuca ranks better than 53.85% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Neuca's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:NEU vs MCK, COR, CAH: Buyback Yield % Comparison
For the Medical Distribution subindustry, Neuca's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuca Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Neuca's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Neuca's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuca (WAR:NEU) has a Buyback Yield % of 0.11 as of Jul. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neuca and its competitors. This is 89% below median its historical median of 1.00. According to the industry distribution chart, Neuca ranks #18 out of 39 companies in the Medical Distribution industry, placing it in the top 46.2%.
Is Neuca's Buyback Yield % too high?
Neuca's current Buyback Yield % of 0.11 is 89% below median its 10-year median of 1.00. Based on the distribution chart, Neuca ranks #18 out of 39 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Neuca has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neuca's Buyback Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Neuca ranks #18 out of 39 companies for Buyback Yield %. This puts Neuca in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
A good Buyback Yield % depends on the Medical Distribution industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neuca and its competitors. Neuca's current Buyback Yield % is 0.11, which is 89% below median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuca stock overvalued right now?
Based on GuruFocus' analysis, Neuca (WAR:NEU) is currently considered Modestly Undervalued. The stock's GF Value™ is zł896.12, compared to a current price of zł742.00 — trading 17.2% below its estimated fair value. The current Buyback Yield % is 0.11, which is 89% below median its 10-year median of 1.00. Neuca's overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Neuca (WAR:NEU), the current Buyback Yield % is 0.11 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuca (WAR:NEU) Overvalued in 2026?
Based on GuruFocus' analysis, Neuca stock appears to be undervalued.
The current stock price of zł742.00 is trading 17.2% below its estimated GF Value™ of zł896.12.
GuruFocus considers Neuca to be Modestly Undervalued.
Key valuation signals for WAR:NEU:
Buyback Yield %: 0.11 (89% below median its 10-year median of 1.00)
GF Value™: zł896.12 vs. price of zł742.00 (17.2% below fair value)
No single metric tells the full story. See the WAR:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuca SA is a wholesale distributor of pharmaceuticals in Poland. The company's segment includes Pharmacy wholesale; Manufacture of pharmaceuticals; Outpatient medical care clinics; Clinical trials and Insurance activities. It generates maximum revenue from the Pharmacy wholesale segment.
97GF Score
Get the complete analysis for WAR:NEU
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:NEU has been successfully added to your 
